Adagio Medical (NASDAQ:ADGM) vs. Anteris Technologies Global (NASDAQ:AVR) Financial Analysis

Adagio Medical (NASDAQ:ADGM) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Adagio Medical and Anteris Technologies Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-661.85%	-73.35%
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%

Risk & Volatility

Adagio Medical has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500.

Insider and Institutional Ownership

48.1% of Adagio Medical shares are held by institutional investors. 7.8% of Adagio Medical shares are held by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Adagio Medical and Anteris Technologies Global”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$600,000.00	5.77	-$25.08 million	($1.48)	-0.11
Anteris Technologies Global	$1.91 million	388.31	-$94.14 million	($1.95)	-3.90

Adagio Medical has higher earnings, but lower revenue than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Adagio Medical and Anteris Technologies Global, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1	1	2	0	2.25
Anteris Technologies Global	1	0	4	0	2.60

Adagio Medical currently has a consensus target price of $3.50, suggesting a potential upside of 2,143.59%. Anteris Technologies Global has a consensus target price of $16.00, suggesting a potential upside of 110.25%. Given Adagio Medical’s higher possible upside, equities analysts plainly believe Adagio Medical is more favorable than Anteris Technologies Global.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.